

Matthew F Covington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4126081/publications.pdf>

Version: 2024-02-01

35
papers

413
citations

1040056

9
h-index

794594

19
g-index

35
all docs

35
docs citations

35
times ranked

434
citing authors

#	ARTICLE	IF	CITATIONS
1	Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1350-1356.	1.5	80
2	The Future of Contrast-Enhanced Mammography. <i>American Journal of Roentgenology</i> , 2018, 210, 292-300.	2.2	59
3	Signs and Artifacts in Amyloid PET. <i>Radiographics</i> , 2018, 38, 2123-2133.	3.3	42
4	Accuracy of Unenhanced MR Imaging in the Detection of Acute Appendicitis: Single-Institution Clinical Performance Review. <i>Radiology</i> , 2016, 279, 451-460.	7.3	36
5	Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy. <i>Breast Journal</i> , 2018, 24, 1010-1014.	1.0	22
6	Comparative Benefit-to-Radiation Risk Ratio of Molecular Breast Imaging, Two-Dimensional Full-Field Digital Mammography with and without Tomosynthesis, and Synthetic Mammography with Tomosynthesis. <i>Radiology Imaging Cancer</i> , 2019, 1, e190005.	1.6	19
7	Contrast-Enhanced Mammography Implementation, Performance, and Use for Supplemental Breast Cancer Screening. <i>Radiologic Clinics of North America</i> , 2021, 59, 113-128.	1.8	18
8	Classification Schema of Symptomatic Enterogastric Reflux Utilizing Sincalide Augmentation on Hepatobiliary Scintigraphy. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 198-202.	0.8	12
9	PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies. <i>Cancers</i> , 2022, 14, 3000.	3.7	11
10	FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec. <i>Clinical Nuclear Medicine</i> , 2017, 42, 114-115.	1.3	9
11	Advances and Future Directions in Molecular Breast Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 17-21.	5.0	9
12	Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging. <i>PLoS ONE</i> , 2015, 10, e0134457.	2.5	8
13	FDG PET/CT and Ultrasound Evaluation of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2020, 45, 68-73.	1.3	8
14	Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 615-630.	2.5	8
15	Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics. <i>Clinical Nuclear Medicine</i> , 2022, 47, 488-495.	1.3	8
16	Molecular Breast Imaging and the 2016 Update to the ACR Appropriateness Criteria for Breast Cancer Screening. <i>Journal of the American College of Radiology</i> , 2016, 13, 1408.	1.8	7
17	PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies. <i>Cancers</i> , 2022, 14, 2668.	3.7	7
18	American College of Radiology Accreditation, Performance Metrics, Reimbursement, and Economic Considerations in Breast MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 303-314.	1.1	6

#	ARTICLE	IF	CITATIONS
19	PET-CT in Clinical Adult Oncology—V. Head and Neck and Neuro Oncology. <i>Cancers</i> , 2022, 14, 2726.	3.7	6
20	Pitfalls in the Performance and Interpretation of Scintigraphic Imaging for Pleuroperitoneal Shunt. <i>Clinical Nuclear Medicine</i> , 2016, 41, 858-861.	1.3	5
21	Optimal Time Points for Scintigraphic Imaging of Pleuroperitoneal Shunts. <i>Clinical Nuclear Medicine</i> , 2016, 41, 766-768.	1.3	5
22	Prospective assessment of adjunctive ultrasound-guided diffuse optical tomography in women undergoing breast biopsy: Impact on BI-RADS assessments. <i>European Journal of Radiology</i> , 2021, 145, 110029.	2.6	5
23	PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies. <i>Cancers</i> , 2022, 14, 2689.	3.7	4
24	PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 2835.	3.7	4
25	Ultrasound Elastography May Better Characterize BI-RADS 3 and BI-RADS 4A Lesions to Decrease False-Positive Breast Biopsy Rates and Enable Earlier Detection of Breast Cancer. <i>Journal of the American College of Radiology</i> , 2022, , .	1.8	3
26	Adjusting ACR Appropriateness Criteria—for Novel Radiopharmaceuticals. <i>Journal of the American College of Radiology</i> , 2015, 12, 1242-1243.	1.8	2
27	Impact of Reimbursement Cuts on the Sustainability and Accessibility of Dopamine Transporter Imaging. <i>Journal of the American College of Radiology</i> , 2016, 13, 1039-1043.	1.8	2
28	Accuracy of Dopamine Transporter Imaging with ¹²³ I-Ioflupane in Hispanic and Non-Hispanic Patients. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 154-157.	0.8	2
29	A Graduate's Perspective on the ABR Dual—Certification Pathway in Nuclear Radiology—Diagnostic Radiology. <i>Journal of the American College of Radiology</i> , 2016, 13, 1369-1370.	1.8	1
30	Molecular Breast Imaging Under Threat by the Protecting Access to Medicare Act and ACR Appropriate Use Criteria. <i>Journal of the American College of Radiology</i> , 2020, 17, 445.	1.8	1
31	Molecular Breast Imaging at Ultra-Low Radiation Dose. <i>American Journal of Roentgenology</i> , 2020, 215, W30-W30.	2.2	1
32	Comparison of Country of Origin, Research Collaborations, and Funding for Original Scientific Publications in the <i>Journal of Radiology</i> from 2009 and 2019. <i>Radiology</i> , 2021, 299, E221-E222.	7.3	1
33	Impact of Time Awake and Hours Slept at Night on Radiologists—Mammogram Interpretations: Why We Must Not Burn Out on Radiologist Burnout. <i>Journal of the American College of Radiology</i> , 2021, 18, 739-740.	1.8	1
34	At Which Mean Glandular Dose Does the Benefit of Breast Cancer Deaths Averted Equal the Risk of Lives Lost to Screening From Radiation-induced Malignancy for Mammography With and Without Tomosynthesis?. <i>Journal of Breast Imaging</i> , 2022, 4, 25-30.	1.3	1
35	Molecular Breast Imaging Deserves Fair and Balanced Consideration. <i>Journal of Breast Imaging</i> , 2020, 2, 519-519.	1.3	0